article thumbnail

A Win for Indiana Patients: “Share the Savings” Legislation Now Law

PhRMA

This new law will ensure that Indiana patients aren’t paying more for their medicines than their health insurance company or the middlemen known as pharmacy benefit managers (PBMs).

article thumbnail

How much is Combivent Respimat without insurance?

The Checkup by Singlecare

Plus, we’ve got tips on how to save, even if you don’t have insurance. How much does Combivent Respimat cost without insurance? For people who don’t have insurance or Medicare—or whose plans don’t cover Combivent Respimat—the average retail price is $636 for a 4 gm of 20–100 mcg/act inhaler with 120 inhalations. Many times, yes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How much is NP Thyroid without insurance?

The Checkup by Singlecare

NP Thyroid costs about $59 without insurance for 30, 60 mg tablets. NP Thyroid is derived from a natural source, the thyroid glands of pigs, and it is made by the pharmaceutical company Acella. Is NP Thyroid covered by insurance? How much does NP Thyroid cost without insurance? What is the generic for NP Thyroid?

article thumbnail

STAT+: What pharma companies and insurers think about Medicare’s plan to cover digital treatments

STAT

But it wasn’t only the startups and their supporters that took notice — some of the largest pharma and health care companies in the country, like Pfizer and CVS Health, weighed in on the proposal during the comment period, arguing for modifications that suit their vision for how digital treatments ought to be valued.

Insurance 136
article thumbnail

STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum

STAT

The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

article thumbnail

STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients

STAT

Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its biosimilar version of Humira – the world’s best-selling medicine – and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patients.

article thumbnail

STAT+: Pharmalittle: Cystic fibrosis patients caught in battle between pharma and insurers; Merck Covid pill fails to prevent infection among household members

STAT

… A growing number of cystic fibrosis patients and their families are getting caught in the middle of a grinding, behind-the-scenes struggle that is taking place between pharmaceutical companies and health insurers across the U.S. in response to the rising cost of prescription medicines , STAT explains.